Continuity and Strategy: Fresenius Management SE Proactively Extends CFO Sara Hennicken’s Mandate

Continuity and Strategy: Fresenius Management SE Proactively Extends CFO Sara Hennicken’s Mandate

(IN BRIEF) Fresenius Management SE has extended Sara Hennicken’s term as Chief Financial Officer (CFO) until 2027, two years earlier than planned, to ensure continuity in advancing the #FutureFresenius strategy. Hennicken, who joined Fresenius in 2019, has been instrumental in enhancing transparency within the finance function. The company’s strategy focuses on its operating units, Fresenius Kabi and Fresenius Helios, which hold leading positions in growth markets. To boost performance, a new financial management system has been introduced, including ambitious EBIT margin targets as part of the Fresenius Financial Framework.

(PRESS RELEASE) BAD HOMBURG, Germany, 8-Mar-2024 — /EuropaWire/ — Fresenius SE & Co. KGaA (ETR: FRE), an industry-leading, therapy-focused healthcare company, announces that its Supervisory Board has decided to extend Sara Hennicken’s tenure as Chief Financial Officer (CFO) until 2027, two years ahead of schedule. Originally set to conclude in 2025, this proactive move underscores the company’s commitment to continuity on the Management Board and its dedication to advancing the #FutureFresenius strategy.

Wolfgang Kirsch, Chairman of the Supervisory Board of Fresenius, remarked, “Sara Hennicken has successfully helped drive #FutureFresenius. In doing so, she has significantly improved the transparency in the finance function – this is an important prerequisite for managing the company and its businesses. We are very much looking forward to continuing our collaboration with her.”

Sara Hennicken, aged 43, assumed the role of Chief Financial Officer at Fresenius on September 1, 2022. She initially joined the company in 2019 as Senior Vice President Global Treasury & Corporate Finance for both Fresenius and Fresenius Medical Care. Prior to her tenure at Fresenius, Hennicken spent 14 years in investment banking, including a notable nine-year stint at Deutsche Bank. Her most recent role was as Managing Director and Senior Client Executive in the Corporate Finance Coverage division. Hennicken’s professional journey also includes five years at Citigroup, where she worked in Frankfurt and London. She holds degrees in economics and business administration from institutions in Germany and the USA.

Under the #FutureFresenius strategy, Fresenius is directing its focus towards its operating entities, Fresenius Kabi and Fresenius Helios. These segments hold leading positions in promising growth markets and span across three pivotal growth platforms in the therapy sector: (Bio)Pharma, MedTech, and Care Provision. In a bid to bolster the company’s performance, the Management Board has introduced a streamlined financial management system as a key component of #FutureFresenius. This initiative includes the establishment of ambitious EBIT margin bands for the business segments within the Fresenius Financial Framework, serving as benchmarks for management decisions.

Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE) is a global healthcare company headquartered in Bad Homburg v. d. Höhe, Germany. In the 2023 fiscal year, Fresenius generated €22.3 billion in annual revenue with its more than 190,000 employees. Fresenius offers solutions to the social challenges posed by a growing and ageing population and the resulting need for affordable, high-quality healthcare. The Fresenius Group comprises the operating companies Fresenius Kabi and Fresenius Helios as well as the investment companies Fresenius Vamed and Fresenius Medical Care. With 140 hospitals and countless outpatient facilities, Fresenius Helios is the leading private hospital operator in Germany and Spain, treating around 26 million patients every year. Fresenius Kabi’s product portfolio includes a range of highly complex biopharmaceuticals, clinical nutrition, medical technology, and generic intravenous drugs. Fresenius was established in 1912 by the Frankfurt pharmacist Dr. Eduard Fresenius. After his death, Else Kröner took over management of the company in 1952. She laid the foundations for a global enterprise that today pursues the goal of improving people’s health. The largest shareholder is the nonprofit Else Kröner-Fresenius Foundation, which is dedicated to advancing medical research and supporting humanitarian projects.

For more information visit the company website at www.fresenius.com.
Follow us on social media: www.fresenius.com/socialmedia

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts.
Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Fresenius SE & Co. KGaA

Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Wolfgang Kirsch
General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Sara Hennicken, Robert Möller, Dr. Michael Moser Chairman of the Supervisory Board: Wolfgang Kirsch

Media contact:

Leif Heussen
Corporate Communications
Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
T +49 6172 608-4030
F +49 6172 608-2294
leif.heussen@fresenius.com
www.fresenius.com

SOURCE: Fresenius SE & Co. KGaA